Cite
APA Citation
Kaul, M., End, P., Cabanski, M., Schuhler, C., Jakab, A., Kistowska, M., Kinhikar, A., Maiolica, A., Sinn, A., Fuhr, R., & Cenni, B. (2021). remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and translational science, 14(5), 1756–1768. http://access.bl.uk/ark:/81055/vdc_100144249995.0x000012